Strides Pharma Science Limited has informed the Exchange regarding a press release dated January 30, 2026, titled "Strides Continues to Deliver Exceptional Performance With Highest Ever Quarterly EBITDA of ₹2,359m in Q3FY26".
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Strides Pharma Science has shared a press release dated January 30, 2026, highlighting its Q3FY26 results. The company reported its highest-ever quarterly EBITDA of ₹2,359 million, describing the performance as exceptional. This marks a significant milestone in the company's quarterly earnings history. The press release underscores continued strong operational performance during the third quarter of FY26.
Record-high quarterly EBITDA signals strong operational momentum and is likely to be viewed positively by investors, potentially supporting stock price sentiment in the near term.